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Background: The combretastatins are a class of natural stilbenoids. These molecules generally share three common
structural features: a trimethoxy "A"-ring, a "B"-ring containing substituent often at C3′ and C4′, and an ethene
bridge between the two rings, which provides necessary structural rigidity. Members of the combretastatin family
possess varying ability to cause vascular disruption in tumors. Combretastatin binds to the colchicine binding site of
β-subunit of tubulin. Despite having a similar name, combretastatin is unrelated to statins, a family of cholesterol-
lowering drugs.
Results: New combretastatin 2-(1-acetyl-1H-indole-3-yl)-3-(phenyl) propenoic analogues (2a to 2y), bearing indole
moiety at the place of ring A of combretastatin (CA4), were synthesized and evaluated for anticancer activity
against various cancer cell lines such as THP-1 (leukemia), A-549 (lung), IGROV-1 (ovary), HEP-2 (liver), MCF-7 (breast),
and DU-145 (prostate). Compound 2d showed anti-cancer activity against THP-1 and MCF-7 with IC50 0.80 and
0.37 μM, respectively, and 2y showed against MCF-7 with IC50 3.60 μM comparable to paclitaxel.
Conclusions: The target compounds bind to the colchicine binding site which is situated at α and β interface of
tubulin and prevent polymerization as it was confirmed by immunofluorescence technique. The molecular docking
further confirmed the binding of the potent compound 2d to the colchicine binding site at α and β interface of
tubulin.
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Tubulin is a useful biochemical target for various clinic-
ally used anticancer drugs like paclitaxel, vincristine,
and vinblastine (Figure 1) [1]. It plays an important role
in the formation of the mitotic spindle which provides
the structural framework for the physical segregation of
the chromosomes during the mitosis [2]. Microtubules,
made from tubulin are highly dynamic cytoskeleton
elements in eukaryotic cells and play a critical role in
various processes like mitosis, cell shape, intracellular
organelle, transport and cell-cell interactions, and signal
transduction [3,4]. They have highly polar structure and
favor growth at the plus (+) end and shrinkage at the
minus (−) end. This dynamic equilibrium can be* Correspondence: suniliftm1982@gmail.com
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in any medium, provided the original work is paffected by treatment with some agents like phenstatin,
chalcone, lignan, colchicine, and podophyllotoxin ultim-
ately prevent mitosis, thus used for cancer treatment
[5,6]. Drugs which target tubulin interact with mitotic
spindle and act by binding to the following binding sites:
(1) colchicine binding site, (2) vinca alkaloid binding
site, (3) rhizoxin/maytansine binding site, (4) tubulin
sulfhydryl binding site, and (5) unknown binding sites
[1]. Taxol binds to the β-tubulin of colchicine binding site
and stabilizes microtubule against depolymerization.
Colchicine binds to the α-tubulin of colchicine binding
site and blocks the polymerization of microtubule [7].
Combretastatins binds to β-tubulin of colchicine binding
site, strongly inhibits tubulin polymerization [8-10], and
disrupts the normal mitotic spindle function [11]. It was
first isolated from the bark of African willow tree
Combretum caffrum [12]. Various analogues have been
synthesized and showed very good anticancer activity by
inhibiting tubulin polymerization [13]. Earlier synthesizedn Open Access article distributed under the terms of the Creative Commons





























































Figure 1 Some reported tubulin inhibitors.
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http://www.orgmedchemlett.com/content/3/1/3compounds were having two rings in cis-configuration,
but Pettit et al. have synthesized resveratrol type of com-
pounds, β-nitrostyrenes, in which two rings are in trans-
configuration and have marked antitumor activity. They
also have synthesized E-indole nitrostyrene which showed
marked anticancer activity [14]. Anticancer agents vincris-
tine and vinblastine derived from Catheranthus roseus
have been useful in cancer treatment, and this effect is due
to the interaction of these drugs with tubulin [8,15]. It was
thought worthwhile to incorporate another ring system
having indole nucleus to rationally design combretastatin-
like compounds replacing one ring with indole moiety
because vincristine, vinblastine, elliptinium [16], and
bromoindirubin contain indole moiety and have good
tubulin polymerization inhibitory property [17]. Resist-
ance remains a significant problem in the treatment of
cancer with taxol like many chemotherapeutic agents,
and it is caused by alterations in microtubule dynamics
[18]. Our aim was to synthesize tubulin inhibitors
having indole ring as basic moiety.
Methods
Combretastatin 2-(1-acetyl-1H-indole-3-yl)-3-(phenyl) pro-
penoic analogues (2a to 2y) were synthesized by condensa-
tion of indole-3-acetic acid with different substituted
aldehydes using triethyl amine and acetic anhydride (shownin Scheme 1). For anticancer activity, seven cancer cell lines
like lung (A-549), ovary (IGROV-1), prostate (DU-145),
liver (HEP-2), leukemia (THP-1), and breast (MCF-7) were
used.Materials and methods of immunofluorescence confocal
microscopy
THP1 cells (8 × 10 [4] cells/well) were seeded onto 18-mm
square coverslips in six well plates. Cells were allowed to
adhere for 24 h before dosing with required concentra-
tions of 2d. Paclitaxel 1 μM was used as a positive
control. After the treatment period, cells were fixed in
4% paraformaldehyde for 10 min at room temperature
and permeabilized using 0.5% Triton-X (Sigma-Aldrich,
MO, USA) in PBS for 5 min. The cells were blocked with
10% goat serum for 20 min at room temperature. Micro-
tubules were detected with a monoclonal α-tubulin
antibody (Sigma Corporation, Cream Ridge, USA) di-
luted 1:100 in 0.1% Triton X-100 in PBS for 1 hr 37°C
and Alexa Fluor 488 conjugated secondary antibody
(Invitrogen, Carlsbad, USA) diluted 1:1,000 in PBS for
1 hr at room temperature. Cells were then washed three
times in PBS and stained with DAPI diluted 1:1,000 in
PBS [5]. The coverslips were mounted over glass slides,















Scheme 1 Reagents and conditions. (A) Triethylamine; (B) acetic anhydride, refluxed for 6 to 10 h.
Kumar et al. Organic and Medicinal Chemistry Letters 2013, 3:3 Page 3 of 13
http://www.orgmedchemlett.com/content/3/1/3an Olympus Fluoview FV1000 laser scanning microscope
(Olympus Inc., Center Valley, USA).
Material and methods for molecular docking
The coordinates of tubulin were obtained from protein
data bank [PDB:1SA0] [19,20]. The structure of 2d was
drawn in ChemDraw [21] and subjected to energy
minimization in the MOPAC module, using the AM1
procedure and implemented in the CS Chem3D Ultra
(Cambridge Soft Corporation, Cambridge, USA). The
2d was docked in to the colchicine binding site of tubu-
lin using the GOLD 5.0.1 software [22]. GOLD performs
genetic algorithm-based ligand docking to optimize the
conformation of the ligand at the receptor binding site.
It utilizes Gold score fitness function to evaluate the
various conformations of the ligand at the binding site
and comprises four components: protein-ligand hydro-
gen bond energy, protein-ligand van der Waals (vdw)
energy, ligand internal vdw energy, and ligand torsional
strain energy. The compound was docked ten times,
and each pose was ranked according to its Gold score
fitness function. The conformation with the highest
score was selected for discussion.
Results and discussion
Chemistry
Twenty-five combretastatin analogues (2a to 2y) were
synthesized by condensation of indole-3-acetic acid (1)
with different substituted aldehydes (2) using triethyl
amine and acetic anhydride as reported previously (shown
in Scheme 1) [23]. The reaction was monitored by TLC.
The compounds were purified (yield 48% to 63%) by
column chromatography using silica gel mesh size of 60
to 120. All the synthesized compounds (Figure 2) were
characterized by spectroscopic techniques like infrared
spectrometry (IR), mass spectrometry (MS), and nuclear
magnetic resonance spectroscopy (NMR) (1H NMR, 13C
NMR, heteronuclear multiple bond correlation (HMBC)
NMR (Figure 3 and Table 1), and heteronuclear single
quantum coherence (HSQC). 1H NMR indicates that
H-7′ is highly deshielded as it appears to lie in thedeshielding cone of N-acetyl group. H-3 is deshielded
because of its nearby carbonyl of N-acetyl. H-3 is also
deshielded because of its β position to carbonyl, but it is
less deshielded than H-7′ because it does not come under
the influence of magnetic anisotropy of carbonyl. No
change in the integration of the H-3 was observed when
H-2′ was doubly irradiated. These results indicated that
H-2′ and H-3 are not in the close proximity. This is pos-
sible only when two rings are trans to each other. If two
rings would have been in cis configuration, double irradi-
ation of H-2′ would have resulted in signal enhancement
of H-3 due to nuclear Overhauser effect (nOe). It was
further confirmed that when a compound with hydroxyl
located at 2″ was synthesized, the free OH (at 2″) is used
in the formation of lactone because the geometry is such
where OH and C =O are close in space and prefer to form
lactone. H-3 gets more deshielded than H-7′ because it
comes in the deshielding cone in the plane of benzene
ring as well as the deshielding cone of carbonyl. IR value
of carbonyl shifted to 1,763 from 1,710 because of lactone
formation. Further Pschorr reaction [24] is fully supported
in the condensation of phenyl acetic acid with aldehyde,
resulting into combretastatin with cis configuration. When
2-hdroxybenzaldehyde is used for the condensation with
phenyl acetic acid, no lactone formation occurred (Figure 4).
From the above observations, it was thus concluded
that synthesized compounds are having two rings in
trans-configuration.
Anticancer activity
All the synthesized compounds were evaluated for an-
ticancer activity (Table 2) against lung (A-549), ovary
(IGROV-1), prostate (DU-145), liver (HEP-2), leukemia
(THP-1), and breast (MCF-7) cancer cell lines. Com-
pounds 2j, 2 k, and 2r showed good anticancer activity
against THP-1, DU-145, and MCF-7 cell lines. How-
ever, compounds 2d (IC50 = 0.80 and 0.37 μM) and
2y (IC50 = 3.6 μM) showed marked anticancer activity.
The italicized values indicate significant activity.
Synthesized compounds, in spite of having basic
indole moiety, bind to colchicine binding site instead of
2a, R3, R4, R5 = OCH3; R2, R6 = H
2b, R2, R3, R4 = OCH3; R5, R6 = H
2c, R3, R4 = OCH3; R2, R5, R6 = H
2d, R4 = N(CH3)2; R2, R3, R5, R6 = H
2e, R2+ R3 = O-CH2-O; R4, R5, R6 = H
2f, R2 = NO2; R3, R4, R5, R6 = H































2h, R2, R3 = Cl; R4, R5, R6 = H
2i, R2, R4, R5 = OCH3; R3, R6 = H
2j, R2 = Br; R3, R4, R5, R6 = H
2l, R3 = Br; R2, R4, R5, R6 = H
2m, R2 = OCH3; R3, R4, R5, R6 = H
2n, R3 = OH;R4 = OCH3; R2, R5, R6 = H
2o, R4 = OH;R3 = OCH3; R2, R5, R6 = H
2p, R2, R5 = OCH3; R3, R4, R6 = H
2s, R4 = NO2; R2, R3, R5, R6 = H
2t, R4 = F; R2, R3, R5, R6 = H
2u,R3 = Cl; R2, R4, R5, R6 = H
2v, R2 = Cl; R3, R4, R5, R6 = H






Figure 2 Chemical structures of the synthesized compounds.
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http://www.orgmedchemlett.com/content/3/1/3vinblastine binding site because vincristine and vinblast-
ine molecules are very large molecules, and thus, their
binding sites have enlarged cavity as the binding site,
while the present synthesized compounds, being much
smaller in overall dimensions, appear to roll around in
the vinblastine site. Further, this was confirmed by
immunofluorescence confocal microscopy.
Immunofluorescence confocal microscopy
The immunofluorescence technique was used to evalu-
ate the effect of 2d on microtubules. The effect on
microtubule structure was determined using confocal
microscopy. Figure 5 shows representative images of
microtubule structures and nuclei at 24 h of treatment.
Minor changes in the microtubule structure were
observed for 10 μM of 2d at 24 h of treatment. At30 μM, 2d treatment at 24 h induced complete loss of
microtubules. At the 48 h time point, cells treated with
10 and 20 μM 2d showed a dose-dependent disruption and
loss of microtubules compared to the control. Paclitaxel
1 μM was used as positive control. These results indicate
that apoptosis induced by 2d involves a severe loss of
microtubule structure.
Molecular docking of 2d
In order to investigate the recognition process of these
inhibitors at the colchicine-binding site of tubulin, a
flexible docking study was performed on the most potent
compound 2d with the help of GOLD software [22]. The
colchicine binding site encompasses the residues of both
α and β subunits of tubulin (Figure 6). To validate the
docking procedure for the prediction of the correct




























Figure 3 Selected HMBCs of 2e. Red ring indicates the correlation
of two carbons or hydrogens which are near to each other.
Kumar et al. Organic and Medicinal Chemistry Letters 2013, 3:3 Page 5 of 13
http://www.orgmedchemlett.com/content/3/1/3binding mode of inhibitor at the colchicine-binding site,
the colchicine was extracted from the original X-ray struc-
ture [PDB:1SA0] [19,20] and re-docked using GOLD.21.
The highest scoring conformation was selected and com-
pared with X-ray structure conformation. The docked
conformation of colchicine using GOLD was found to be
similar with the original X-ray structure (Figure 7A). The
root mean square deviation between the best scored
conformers from docking and X-ray structure was found
to be 0.72 Å. The compound 2d was docked at the colchi-
cine binding site of tubulin, and the best fit conformation
was selected on the basis of Gold score and visual inspec-
tion. The Figure 7B shows the binding conformation of 2d
at the colchicine binding site. The compound 2d gets
stabilized at the colchicine-binding site of tubulin by
hydrophobic and hydrogen bond interactions. The aro-
matic part of indole ring gets positioned in a hydrophobic
cavity formed by Leu255β, Ala250β, Ala316β, Val318β,
and Ala354β. The carbonyl oxygen (carbonyl group atTable 1 Three-bond [1] H- [13]C coupling (HMBC) in 2e
Serial number H C
1 H-3 C-3’, C-2″




6 H-6’’ C-3, C-1indole) forms a hydrogen bond with sulfhydryl group of
Cys241β. This is similar to the interaction of colchicines
with the tubulin [25]. Another hydrogen bond was formed
between the hydroxyl group of the carboxylic acid part of
2d and nitrogen of Leu255β. These two hydrogen bonds
play crucial role in stabilizing the conformation of 2d at
the colchicine-binding site. The unsaturated intermediate
chain between rings A and B of 2d is placed in close
vicinity of the side-chain of Leu248β (Figure 7B). The ring
B of 2d is extended towards the α-chain of the tubulin.
The docking study was helpful to find the binding
conformation of 2d at the colchicine binding site of
tubulin.
Experimental
The reagents were purchased from Sigma-Aldrich (MO,
USA), LobaChemie (Mumbia, India), and Central Drug
House (New Delhi, India) and used without further
purification. All yields refer to isolated products after
purification. Products were characterized by spectro-
scopic data (IR, [1] H NMR, and [13] C NMR spectra).
The spectra were measured in DMSO-d6 relative to
TMS (0.00 ppm). IR (KBr pallets) spectra were recorded
on a Fourier transform infrared Thermo spectropho-
tometer (ThermoFisher Scientific Inc., Waltham, USA).
Melting points were determined in open capillaries and
were found to be uncorrected.
Typical experimental procedure for the synthesis
combretastatin 2-(1-acetyl-1H-indole-3-yl)-3-(phenyl)
propenoic analogues (2a to 2y)
A mixture of IAA (0.0057 mmol), substituted benzalde-
hyde (0.0057 mmol) and triethylamine (2 ml) in Ac2O
(4 ml), was heated until the reaction was complete. After
cooling, the reaction mixture was acidified with 35% aque-
ous HCl (6 ml) and kept at room temperature overnight
when precipitates appeared as such or on dilution with
Table 2 Anticancer activity of synthesized compounds
Compound code IC50 of cell line types (tissue/cell)
THP-1 A-549 MCF-7 IGROV-1 HEP-2 DU-145
(WBC) (lung) (breast) (ovary) (liver) (prostrate)
2a >100 >100 86.9 >100 >100 >100
2b >100 >100 >100 >100 - -
2c 89.2 71.0 >100 >100 - -
2d 0.80 >100 0.37 38.0 63.4 40.4
2e 73.0 >100 >100 >100 - -
2f 81.3 >100 >100 >100 >100 >100
2 g 70.6 >100 >100 - 89 >100
2 h >100 >100 >100 - >100 -
2i - - >100 - - -
2j >100 >100 76.1 - - 16.4
2 k >100 >100 50.0 - - 43.9
2 l 86.0 >100 76.4 >100 >100 >100
2 m 67.0 75.7 >100 >100 >100 >100
2n >100 >100 >100 >100 - -
2o >100 >100 >100 >100 - -
2p >100 >100 >100 >100 - -
2q 68.0 >100 79.0 >100 >100 >100
2r 40.8 38.7 51.9 >100 >100 >100
2 s >100 90.3 >100 >100 >100 >100
2 t - >100 >100 - >100 >100
2u >100 >100 >100 >100 >100 >100
2v >100 >100 95.2 >100 - -
2w >100 >100 51.8 >100 - -
2x 92.0 >100 >100 >100 >100 >100
2y 81.8 49.8 3.6 >100 85.3 -
Adriamycin 0.12 0.11 0.16 0.19 - -
Mitomycin 0.23 0.19 0.27 0.25 0.31 -
Paclitaxel 0.15 - - 0.15 0.14 -
5-fluorouracil 9.7 8.6 9.9 8.3 9.7 9.1
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Mp: 177°C to 178°C; I.R. (KBr, cm−1): 1722 (C =O), 1681
(C =O, N-acetyl) 1636 (C = C), 1542 (C = C, phenyl ring),
[1] H NMR (500 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.44 (d, 1H, J = 8.25, H-7′), 8.03 (s, 1H, H-3), 7.90 (s, 1H,
H-2′), 7.42 (1H, dd, J = 7.9 and 7.8, H-5′), 7.31 (dd, 1H,
J = 7.7 and J = 7.8, H-6′), 7.25 (d, 1H, J = 8.0, H-4′), 6.64
(s, 1H, H-2″), 6.57 (s, 1H, H-6″), 3.63 (s, 3H, OMe) 3.34
(s, 6H, 2× OMe) 2.71 (s, 3H, N-acetyl); [13] C NMR
(125 MHz, DMSO-d6, δ, TMS= 0, J =Hz): 169.40, 168.30,
152.20, 141.51, 138.38, 134.86, 129.35, 129.22, 125.95,124.92, 123.46, 122.61, 119.84, 116.64, 115.97, 107.87,
59.96, 55.02, 23.70; MS: 418 (M + Na)+; Anal. calcd. For
C22H21NO6: C, 66.83; H, 5.35; N, 3.54 found C: 66.73;
H, 5.34; N, 3.34.
2b. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2,3,4-trimethoxyphenyl)
propenoic acid
Mp: 210°C to 212°C; I.R. (KBr, cm−1): 1718 (C =O), 1668
(C =O, N-acetyl) 1637 (C = C), 1545 (C = C, phenyl ring);
[1] H NMR (500 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.36 (d, 1H, J = 8.3, H-7′), 8.16 (s, 1H, H-3) 7.84 (s, 1H,
H-2′), 7.31 (dd, 1H, J = 7.3 and 8.0, H-6′), 7.14 (m, 2H,
H-5′, 4′), 6.66 (d, 1H, J = 8.9, H-6″), 6.47 (d, 1H, J = 8.9,
H-5″), 3.89 (s, 3H, OMe), 3.71 (s, 3H, OMe) 3.65 (s, 3H,
OMe) 2.64 (s, 3H, N-acetyl); [13] C NMR (125 MHz,
DMSO-d6, δ, TMS = 0, J = Hz): 169.40, 168.41, 154.55,









Figure 5 Effects of paclitaxel and 2d on microtubules in THP-1 cells. Cells were plated on coverslips and treated with 1 μM paclitaxel and
10 and 20 μM 2d for 48 h. After treatment, cells were fixed and processed for immunofluorescence/confocal microscopy using monoclonal
α-tubulin antibody and secondary antibody conjugated with Alexa-488 (Invitrogen, Carlsbad, USA). 4′,6-diamidino-2-phenylindole (DAPI) was used
for nuclear staining. The untreated cells show normal nuclear morphology and microtubules. Paclitaxel treatment causes the condensation and
fragmentation of nuclei due to apoptosis (arrow) and also causes loss of microtubules (arrowhead). 2d treatment induces concentration-
dependent increase in condensation and fragmentation of nuclei (arrow) due to apoptosis and also concentration-dependent loss of
microtubules (arrowhead). Similar results were obtained in two separate experiments.
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Figure 7 Overlay of crystal structure and binding conformation. (A) Overlay of crystal structure (blue) and docked (purple) conformation of
colchicines, (B) binding conformation of 2d (green) at the colchicine-binding site of tubulin.
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http://www.orgmedchemlett.com/content/3/1/3152.73, 141.32, 135.58, 134.94, 129.29, 126.02, 124.74,
123.99, 123.40, 122.00, 120.78, 119.52, 116.75, 116.03,
107.71, 61.52, 60.39, 55.74, 24.30; MS: 418 (M + Na)+;
Anal. calcd. For C22H21NO6: C, 66.83; H, 5.35; N, 3.54
found C: 66.73; H, 5.34; N, 3.34.
2c. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(3,4-dimethoxyphenyl)
propenoic acid
Mp: 245°C to 247°C; I.R. (KBr, cm−1): 1712 (C =O), 1681
(C =O, N-acetyl) 1638 (C = C), 1554 (C = C, phenyl ring);
[1] H NMR (500 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.38 (d, 1H J = 8.3, H-7′), 7.96 (1H, s, H-3), 7.87 (1H, s,
H-2′), 7.32 (dd, 1H, J = 7.3 and 7.2, H-6′), 7.16 (dd, 1H,
J = 7.1, H-5) 7.12 (d, 1H, J = 7.6, H-4′) 6.97 (dd, 1H,
J = 8.4 and 8.5, H-6″), 6.83 (d, 1H, J = 8.5, H-5″) 6.68
(d, 1H, J = 1.7, H-5″) 3.68 (s, 3H, OMe) 3.09 (s, 3H, OMe)
2.64 (s, 3H, N-acetyl); [13] C NMR (125 MHz, DMSO-d6,
δ, TMS = 0, J =Hz): 168.36, 167.30, 148.80, 146.75, 140.50,
133.85, 128.20, 125.64, 124.80, 123.76, 123.63, 122.34,
119.73, 118.71, 115.79, 114.91, 111.40, 110.12, 54.27,
53.12, 22.70; MS: 388 (M+Na)+; Anal. calcd. For




Mp: 246°C to 248°C; I.R. (KBr, cm−1), 3423 (NH), 1702
(C = O), 1682 (C = O, N-acetyl), 1659 (C = C), 1583 (C =
C, phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ,
TMS = 0, J = Hz): 8.43 (d, 1H J = 8.2, H-7′), 7.99 (s, 1H,
H-3), 7.68 (s, 1H, H-2′), 7.14 to 7.30 (m, 5H, 5′, 6′, 4′,
2″, 6″), 6.20 (d, 2H, J = 8.9), 2.91 (s, 6H, 2× Me) 2.59
(s, 3H, N-acetyl); [13] C NMR (125 MHz, DMSO-d6, δ,
TMS = 0, J = Hz); 169.62, 168.66, 150.83, 143.06, 135.55,132.59, 132.11, 129.69, 124.88, 124.59, 123.43, 121.89,
120.30, 118.39, 117.08, 116.37, 111.24, 23.96; MS: 371
(M + Na)+; Anal. calcd. For C21H20N2O3: C, 72.4; H,
5.79; N, 8.04 found C: 72.1; H, 5.80; N, 8.14.
2e. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(benzo[d][1,3]dixol-6-yl)
propenoic acid
Mp: 243°C to 245°C; I.R. (KBr, cm−1): 1710 (C =O), 1683
(C =O, N-acetyl) 1637 (C = C), 1555 (C = C, phenyl ring);
[1] H NMR (500 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.38 (d, 1H J = 8.3, H-7′), 7.94 (s, 1H, H-3), 7.86 (s, 1H,
H-2′), 7.33 (dd, 1H, J = 7.2 and 8.2, H-5′), 7.17 (dd, 1H,
J = 7.7 and 7.3, H-6′) 7.11 (d, 1H, J = 7.8, H-4′) 6.93
(dd, 1H, J = 7.1 and 1.2, H-6″), 6.80 (d, 1H, J = 8.1, H-5″)
6.67 (s, 1H, H-2″) 5.90 (s, 2H, O-CH2-O) 2.65 (s, 3H,
N-acetyl); [13] C NMR (125 MHz, DMSO-d6, δ, TMS = 0,
J =Hz):169.50, 168.36, 148.26, 147.15, 141.30, 134.94,
129.12, 128.42, 126.17, 126.04, 124.85, 123.46, 121.42,
119.64, 116.51, 116.06, 108.76, 108.32, 101.35, 23.84; MS:
372 (M+Na)+; Anal. calcd. For C20H15NO5: C, 68.76; H,
4.33; N, 4.01 found C: 68.75; H, 4.41; N, 4.11. For further
information, please refer to Additional file 1: Figures S1,
Additional file 2: Figure S2, Additional file 3: Figure S3,
Additional file 4: Figure S4, Additional file 5: Figure S5
and Additional file 6: Figure S6.
2 f. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2-nitrophenyl) propenoic
acid
Mp: 209°C to 210°C; I.R. (KBr, cm−1): 1701 (C =O), 1683
(C =O, N-acetyl), 1655 (C = C), 1560 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.39 (d, 1H J = 8.3, H-7′) 7.94 (s, 1H, H-3) 7.88 (s, 1H,
H-2′) 7.6 to 7.70 (m, 4H, 3″, 4″, 5″, 6″) 7.39 (m, 3H,
H-5′, 6′, 4′) 2.7 (s, 3H, N-acetyl); [13] C NMR
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167.00 148.13, 138.99, 133.58, 133, 42, 130.76, 130.31,
129.04, 128.08, 125.31, 124.76, 124.57, 124.31, 123.36,
119.85, 119.57, 116.46, 23.90; MS: 373 (M + Na)+; Anal.
calcd. For C19H14N2O5: C, 65.14; H, 4.03; N, 8.0 found
C: 65.12; H, 4.03; N, 8.12.2 g. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(4-chlorophenyl)
propenoic acid
Mp: 208°C to 209°C; I.R. (KBr, cm−1): 1713 (C =O), 1673
(C =O, N-acetyl), 1633 (C = C), 1580 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.38 (d, 1H J = 8.9, H-7′), 7.99 (s, 1H, H-3) 7.58 to 7.61
(m, 4H, H-2′, 2″, 3″, 5″) 7.38 to 7.47 (m, 3H, H-5′, 6′,
6″), 7.26 (d, 1H, J = 7.9, 4′) 6.46 (s, 1H, NH, D2O
exchangeable) 2.63 (s, 3H, N-acetyl); [13] C NMR
(125 MHz, DMSO-d6, δ, TMS= 0, J =Hz): 168.67, 167.20,
142.78, 140.25, 135.51, 134.58, 133.49, 131.50, 129.53,
129.13, 128.55, 125.76, 125.15, 124.63, 123.59, 120.20,
119.98, 116.67, 23.71; MS: 362 (M+Na)+; Anal. calcd. For
C19H14NO3Cl: C, 67.16; H, 4.15; N, 4.12 found C: 67.12;
H, 4.23; N, 4.10.2 h. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2,3-dichlorophenyl)
propenoic acid
Mp: 225°C to 227°C; I.R. (KBr, cm−1): 1688 (C =O), 1624
(C = C), 1673 (C =O, N-acetyl), 1559 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.43 (d, 1H J = 8.1, H-7′), 8.09 (s, 1H, H-3) 8.01 (s, 1H,
H-2′), 7.51 to 7.6 (m, 4H, H-6′, 4″, 5″, 6″), 7.26 (d, 2H,
J = 7.9, H-5′, 4′) 6.5 (s, 1H, NH, D2O exchangeable),
2.63 (s, 3H, N-acetyl); [13] C NMR (125 MHz, DMSO-d6,
δ, TMS = 0 J =Hz): 167.67, 140.04, 135.17, 133.70, 132.63,
131.30, 127.49, 125.87, 122.99, 23.90; MS: 397 (M+Na)+;
Anal. calcd. For C19H13NO3Cl2: C, 60.98; H, 3.50; N, 3.74
found C: 60.95; H, 3.50; N, 3.76.2i. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2,4,5-trimethoxyphenyl)
propenoic acid
Mp: 229°C to 230°C; I.R. (KBr, cm−1): 1701 (C =O), 1673
(C =O, N-acetyl), 1603 (C = C), 1514 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.40 (d, 2H, J = 7.2, H-3, 7′), 7.96 (s, 1H, 2′), 7.31 to 7.43
(m, 3H, H-5′, 6′, 4′), 6.47 (s, 1H, D2O exchangeable), 6.40
(d, 2H, J = 7.6, H-5″, 6″), 3.89 (d, 6H, J = 11.3, 2× OMe),
2.9 (d, 3H, OMe) 2.73 (s, 3H, N-acetyl); [13] C NMR
(100 MHz, DMSO-d6, δ, TMS = 0, J = Hz): 169.54,
168.59, 153.80, 151.37, 142.03, 136.41, 135.47, 129.52,
125.09, 124.92, 123.61, 120.56, 119.91, 118.16, 116.40,
114.80, 112.69, 96.29, 56.42, 55.82, 55.01, 23.94; MS:
418 (M + Na)+; Anal. calcd. For C22H21NO6: C, 66.83;
H, 5.35; N, 3.54 found C: 66.85; H, 5.35; N, 3.30.2j. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2-bromophenyl)
propenoic acid
Mp: 199°C to 201°C; I.R. (KBr, cm−1): 1708 (C =O), 1666
(C =O, N-acetyl), 1622 (C = C), 1556 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS= 0,J =Hz): 8.43
(d, 1H, J = 8.7, H-7′), 7.98 (s, 1H, H-3), 7.48 (d, 1H, J =
9.0, H-2′), 7.32 to 7.20 (m, 3H, 6′, 3″, 6″), 7.01 (m, 4H,
5′, 4′, 4″, 6″), 2.64 (s, 3H, N-acetyl); [13] C NMR
(125 MHz, DMSO-d6, δ, TMS = 0, J = Hz): 168.81,
168.68, 140.01, 136.90, 135.53, 133.01, 131.82, 129.75,
128.10, 125.32, 125.28, 125.20, 123.57, 122.11, 120.24,
116.65, 116.51, 24.00; MS: 407 (M + Na)+; Anal. calcd.
For C19H14BrNO3: C, 59.39; H, 3.67; N, 3.65 found C,
59.24; H, 3.56; N, 3.45.
2 k. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(naphthalene-2-yl)
propenoic acid
Mp: 235°C to 237°C; I.R. (KBr, cm−1): 1708 (C =O), 1676
(C =O, N-acetyl), 1637 (C = C), 1560 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.44 (d, 1H, J = 8.2, H-7′), 8.25 (s, 1H, H-3), 7.81 (s, 1H,
H-2′), 7.68 (dd, 2H, J = 6.1 and 2.1, H-3″, 4″), 7.52 (1H,
s, 1″) 7.44 to 7.30 (m, 4H, 8″, 7″, 6″, 4″), 7.11 (m, 3H,
5′, 6′, 4′) 2.6 (s, 3H, N-acetyl); [13] C NMR (125 MHz,
DMSO-d6, δ, TMS = 0, J = Hz); 169.26, 168.73, 142.17,
135.56, 133.27, 132.87, 132.40, 131.33, 129.38, 128.37,
127.64, 127.48, 127.03, 126.32, 126.10, 125.18, 125.13,
123.68, 123.57, 120.38, 117.43, 116.49, 24; MS: 378 (M+
Na)+; Anal. calcd. For C23H17NO3: C, 77.73; H, 4.82; N,
3.94 found C, 77.54; H, 4.64; N, 3.73.
2 l. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(3-bromophenyl)
propenoic acid
Mp: 226°C to 228°C; I.R. (KBr, cm−1): 1708 (C =O), 1676
(C =O, N-acetyl), 1622 (C = C), 1555 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.41 (d, 1H, J = 7.6, H-7′), 7.95 (s, 1H, H-3) 7.75 (s, 1H,
H-2′) 7.30 (dd, 2H, J = 7.1 and 3.3, H-6′), 7.21 to 7.00
(m, 4H, H-6′, 4″, 5″, 6″), 6.98 to 6.8 (m, 2H, H-5′, 4′),
2.65 (s, 3H, N-acetyl); [13] C NMR (100 MHz, DMSO-d6,
δ, TMS = 0, J =Hz): 168.80, 168.63, 139.53, 137.02, 135.45,
132.82, 131.66, 129.76, 128.80, 128.09, 125.76, 125.41,
125.06, 123.47, 122.00, 120.19, 116.69, 116.40, 23.95; MS:
407 (M+Na)+; Anal. calcd. For C19H14BrNO3: C, 59.39;
H, 3.67; Br, 20.80; N, 3.65 found C, 59.56; H, 3.54; N, 3.44.
2 m. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2-methoxyphenyl)
propenoic acid
Mp: 229°C to 231°C; I.R. (KBr, cm−1): 1707 (C =O), ),
1677 (C =O, N-acetyl), 1603 (C = C), 1603 and 1450 (C =
C, phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ,
TMS = 0, J =Hz): 8.44 (d, 1H, J = 8.3, H-7′), 7.96 (s, 1H,
H-3) 7.81 (s, 1H, H-2′), 7.27 (dd, 1H, J = 8.1 and 8.0, H-6′),
7.23 (d, 2H, J = 7.3, H-4″, 6″), 7.13 (dd, 2H, J = 7.6 and 2.9,
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(s, 3H, N-acetyl); [13] C NMR (125 MHz, DMSO-d6, δ,
TMS = 0, J =Hz): 168.45, 160.00, 138.53, 136.19, 134.45,
130.87, 130.17, 129.53, 128.50, 127.89, 126.76, 125.51,
124.96, 123.45, 122.40, 121.09, 116. 23, 115.79, 24.10; MS:
378 (M+Na)+; Anal. calcd. For C20H17NO4: C, 71.63; H,
5.11; N, 4.18 found C, 71.63; H, 5.16; N, 4.26.
2n. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(3-hydroxy-4-
methoxyphenyl) propenoic acid
Mp: 235°C to 237°C; I.R. (KBr, cm−1): 2926 (O-H), 1702
(C = O), 1668 (C = O, N-acetyl), 1638 (C = C), 1504 (C =
C, phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ,
TMS = 0, J = Hz): 8.45 (d, 1H, J = 8.2, H-7′), 7.89 (s, 1H,
H-3), 7.63 (s, 1H, H-2′), 7.29 (dd, 1H, J = 7.0 and 7.1,
H-6′), 7.15 (dd, 2H, J = 7.2 and 7.2, H-5′, 4′), 6.79 to 7.0
(m, 3H, H-2″, 5″, 6″), 3.75 (s, 3H, CH3), 2.64 (s, 3H,
N-acetyl ); [13] C NMR (100 MHz, DMSO-d6, δ, TMS = 0,
J =Hz); 168.5, 168.46, 148.63, 145.65, 141.58, 135.03,
129.17, 127.01, 124.98, 124.31, 122.88, 122.82, 120.41,
119.64, 116.91, 116.15, 115.84, 110.86, 55.12, 23.70; MS:
374 (M+Na)+; Anal. calcd. For C20H17NO5: C, 68.37; H,
4.88; N, 3.99 found C, 68.21; H, 4.62; N, 4.13.
2o. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(4-hydroxy-3-
methoxyphenyl) propenoic acid
Mp: 212°C to 213°C; I.R. (KBr, cm−1): 2930 (OH), 1701
(C = O), 1681 (C = O, N-acetyl), 1599 (C = C), 1451 (C =
C, phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ,
TMS = 0, J = Hz): 9.22 (s, 1H, OH, D2O exchangeable),
8.43 (d, 1H, J = 8.2, H-7′), 8.03 (s, 1H, H-3), 7.83 (s, 1H,
H-2′) 7.30 (dd, 2H, J = 7.2 and 7.3, H-5′, 6′) 6.90 (s, 1H,
H-6″), 6.82 to 6.70 (m, 3H, 4′, 2″, 3″), 3.15 (s, 3H,
OMe) 2.59 (s, 3H, N-acetyl ); [13] C NMR (125 MHz,
DMSO-d6, δ, TMS = 0, J = Hz): 167.88, 167.50, 147.05,
145.72, 141.15, 134.05, 128.11, 124.56, 124.25, 123.93,
123.70, 122.20, 119.07, 118.36, 116.37, 113.91, 111.62,
53.37, 22.70; MS: 374 (M + Na)+; Anal. calcd. For
C20H17NO5: C, 68.37; H, 4.88; N, 3.99 found C, 68.22;
H, 4.71; N, 4.03.
2p. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2,5-dimethoxyphenyl)
propenoic acid
Mp: 246°C to 248°C; I.R. (KBr, cm−1) 1710 (C =O), 1671
(C =O, N-acetyl), 1611 (C = C), 1452 (C = C, phenyl ring);
[1] H NMR(200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.79 (d, 1H, J = 7.2, H-7′), 8.37 (s, 1H, H-3), 8.02 (s, 1H,
H-2′), 7.44 (dd, 1H, J = 8.1 and 8.0, H-6′), 7.17 to 7.20
(m, 2H, H-5′, 4′), 6.90 (d, 1H, J = 2.5, H-2″), 6.88 (d,
1H, J = 7.4, H-5″), 6.77 (d, 1H, J = 7.4, H-6″) 3.50 (s, 3H,
OMe), 3.11 (s, 3H, OMe) 2.71 (s, 3H, N-acetyl ); [13] C
NMR (125 MHz, DMSO-d6, δ, TMS = 0, J = Hz): 167.19,
167.00, 155.04, 150.65, 150.61, 134.72, 133.53, 128.73,
127.69, 124.00, 123.18, 122.07, 121.75, 118.45, 115.47,115.31, 114.53, 112.28, 112.11, 110.27, 22.20; MS: 388
(M + Na)+; Anal. calcd. For C21H19NO5: C, 69.03; H,
5.24; N, 3.83 found C: 69.03; H, 5.37; N, 3.64.
2q. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(furan-2-yl) propenoic
acid
Mp: 231°C to 232°C; I.R. (KBr, cm−1): 1711 (C =O), 1671
(C =O, N-acetyl), 1640 (C = C), 1564 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.49 (d, 1H, J = 8.8, H-7′), 8.00 (s, 1H, H-3) 7.49 (s, 1H,
H-2′) 7.35 (d, 1H, J = 5.3, H-2″), 7.27 to 7.10 (m, 3H,
H-5′, 6′, 4′), 6.20 (dd, 2H, J = 3.4 and 3.5, H-3″, 4”) [13]
C NMR (100 MHz, DMSO-d6, δ, TMS = 0, J = Hz):
168.50, 167.42, 149.78, 142.94, 141.40, 136.61, 134.49,
130.82, 126.00, 125.20, 124.86, 123.28, 122.77, 121.00,
120.42, 111.60, 24.30; MS: 318 (M + Na)+; Anal. calcd.
For C17H13NO4: C: 69.15; H, 4.44; N, 4.74 found C:
69.11; H, 4.53; N, 4.54.
2r. (2Z,4E)-2-(1-acetyl-1H-indol-3-yl)-5-phenylpenta-2, 4-
dienoic acid
Mp: 232°C to 234°C; I.R. (KBr, cm−1): 1725 (C =O), 1671
(C = O, N-acetyl), 1610 (C = C), 1449 (C = C, phenyl
ring); [1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0,
J =Hz): 8.52 (d, 1H, J = 8.4, H-7′), 7.91 (s, 1H, H-3), 7.52
(s, 1H, H-2′), 7.41 to 7.37 (m, 3H, 5′, 6′, 4′), 7.29 to 7.0
(m, 5H, 2″, 3″, 4″, 5″, 6″), 7.03 (dd, 1H, J = 15.5 and
15, H-4), 6.82 (d, 1H, J = 14, H-5), 2.68 (s, 3H, N-acetyl);
[13] C NMR (100 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
170.89, 168.63, 144.60, 142.27, 135.93, 135.51, 130.14,
129.42, 128.82, 127.46, 125.67, 125.52, 124.86, 123.94,
122.09, 120.23, 116.69, 116.08, 24.00; MS: 318 (M+Na)+;
Anal. calcd. For C17H13NO4: C: 76.12; H, 5.17; N, 4.23
found C: 76.23; H, 5.06; N, 4.33.
2 s. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(4-nitrophenyl)
propenoic acid
Mp: 222°C to 223°C; I.R. (KBr, cm−1): 1684 (C =O), 1671
(C =O, N-acetyl), 1629 (C = C), 1601 and 1450 (C = C,
phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ, TMS =
0, J =Hz): 8.41 (d, 1H, J = 8.2, H-7′), 8.32 (s, 1H, H-3),
8.26 (d, 1H, J = 4.7, H-2″), 7.58 to 7.63 (m, 2H, H-2′, 4″),
7.39 (d, 2H, H-4″, 5″), 7.31 to 7.11 (m, 3H, H-5′, 6′, 4′),
2.48 (s, 3H, N-acetyl); [13] C NMR (100 MHz, DMSO-d6,
δ, TMS = 0, J = Hz): 168.00, 167.62, 148.78, 141.94,
136.61, 134.49, 130.82, 124.86, 123.28, 122.77, 24.00;
MS: 373 (M + Na)+; Anal. calcd. For C19H14N2O5: C,
65.14; H, 4.03; N, 8.0 found C: 65.17; H, 4.12; N, 8.05.
2 t. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(4-fluorophenyl)
propenoic acid
Mp: 228°C to 229°C; I.R. (KBr, cm−1): 1711 (C =O), 1679
(C =O, N-acetyl), 1629 (C = C), 1599 and 1450 (C = C,
phenyl ring); [1] H NMR (200 MHz, DMSO-d6, δ,
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H-3), 7.87 (s, 1H, H-2′) 7.33 (m, 3H, 5′, 6′, 4′), 7.07 to
6.9 (m, 4H, 2″, 3″, 5″, 6″), 2.48 (s, 3H, N-acetyl); [13]
C NMR (100 MHz, DMSO-d6, δ, TMS = 0, J = Hz):
169.90, 168.63, 151.00, 140.53, 137.02, 135.45, 132.62,
132.66, 129.36, 126.60, 125.76, 123.47, 122.00, 120.19,
116.69, 116.40, 119.90, 115.70, 24.20: 346 (M + Na)+;
Anal. calcd. For C19H14FNO3: C, 70.58; H, 4.36; N,
4.33 found C, 70.52; H, 4.31; N, 4.23.
2u. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(3-chlorophenyl)
propenoic acid
Mp: 228°C to 229°C; I.R. (KBr, cm−1): 1708 (C =O), 1665
(C = O, N-acetyl), 1623 (C = C), 1449 (C = C, phenyl
ring); [1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0,
J =Hz): 8.38 (d, 1H, J = 8.2, H-7′), 7.99 (s, 1H, H-3), 7.89
(s, 1H, H-2′), 7.31 to 7.50 (m, 6H, 5′, 6′, 4′, 3″, 4″, 5″),
2.48 (s, 3H, N-acetyl); [13] C NMR (125 MHz, DMSO-d
6, δ, TMS = 0, J = Hz): 169.90, 168.63, 151.00, 140.53,
137.02, 135.45, 132.62, 132.66, 129.36, 126.60, 125.76,
123.47, 122.00, 120.19, 116.69, 116.40, 119.90, 115.70,
19.30; MS: 362 (M+Na)+; Anal. calcd. For C19H14NO3Cl:
C, 67.16; H, 4.15; N, 4.12 found C: 67.23; H, 4.11; N, 4.02.
2v. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(2-chlorophenyl)
propenoic acid
Mp: 189°C to 190°C; I.R. (KBr, cm−1): 1720 (C =O), 1685
(C = O, N-acetyl), 1621 (C = C), 1450 (C = C, phenyl
ring); [1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0,
J =Hz): 8.38 (d, 1H, J = 7.32, H-7′), 8.10 (s, 1H, H-3),
7.91 (d, 1H, J = 6.8, H-2′), 7.71 (d, 1H, H-3″), 7.43 to
7.30 (m, 3H, 5′, 6′, 4′), 6.80 to 6.9 (m, 3H, 4″, 5″, 6″),
2.62 (s, 3H, N-acetyl ); [13] C NMR (100 MHz, DMSO-d6,
δ, TMS = 0, J =Hz): 169.80, 168.20, 139.53, 137.02, 135.45,
132.62, 132.66, 129.80, 126.60, 125.76, 123.47, 122.00,
119.00, 116.69, 116.40, 115.7, 24.20; MS: 362 (M+Na)+;
Anal. calcd. For C19H14NO3Cl: C, 67.16; H, 4.15; N, 4.12
found C: 66.27; H, 4.11; N, 4.32.
2w. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(naphthalene-1-yl)
propenoic acid
Mp: 190°C to 192°C; I.R. (KBr, cm−1): 1703 (C =O), 1680
(C =O, N-acetyl), 1615 (C = C), 1449 (C = C, phenyl ring);
[1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J =Hz):
8.23 (d, 1H, J = 7.9, H-7′), 8.16 (s, 1H, H-3), 8.00 (d, 1H,
J = 6.2, H-2′), 7.64 to 7.3 (m, 7H, 2″, 3″, 4″, 5″, 6″, 7″,
8″) 6.93 to 6.80 (m, 3H, 5′, 6′, 4′), 2.60 (s, 3H, N-acetyl);
[13] C NMR (100 MHz, DMSO-d6, δ, TMS = 0, J =Hz);
168.50, 167.88, 140.66, 139.18, 135.56, 133.27, 132.87,
132.40, 131.20, 129.18, 127.64, 126.32, 126.10, 125.18,
123.68, 123.57, 120.38, 117.43, 116.49, 24.20; 378 (M +
Na)+; Anal. calcd. For C23H17NO3: C, 77.73; H, 4.22; N,
3.94 found C, 77.45; H, 4.32; N, 3.83.2x. (Z)-2-(1-acetyl-1H-indol-3-yl)-3-(4-bromophenyl)
propenoic acid
Mp: 220°C to 222°C; I.R. (KBr, cm−1): 1711 (C =O), 1676
(C = O, N-acetyl), 1632 (C = C), 1565 (C = C, phenyl
ring); [1] H NMR (200 MHz, DMSO-d6, δ, TMS = 0,
J =Hz): 8.41 (d, 1H, J = 7.6, H-7′), 7.95 (s, 1H, H-3) 7.75
(s, 1H, H-2′) 7.30 (dd, 2H, J = 7.1 and 3.3, H-6′), 7.21 to
7.10 (m, 4H, H-6′, 3″, 5″, 6″), 6.98 to 6.80 (m, 2H,
H-5′, 4′), 2.68 (s, 3H, N-acetyl); [13] C NMR (125 MHz,
DMSO-d6, δ, TMS = 0, J =Hz): 168.00, 168.53, 139.53,
137.02, 135.45, 132.82, 131.66, 129.76, 128.80, 128.09,
125.76, 125.41, 125.06, 123.47, 122.00, 120.19, 116.69,
116.40, 23.00: 407 (M+Na)+;Anal. calcd. For C19H14
BrNO3: C, 59.39; H, 3.67; N, 3.65; found C, 59.22; H, 3.4;
N, 3.45.
2y. 3-(N-acetyl-1H-indol-3-yl)-8-acetoxy-2H-chromen-2-one
Mp: 110°C to 112°C; I.R. (KBr, cm−1): 1763 (C = O,
lactone) 1710 (C = O, O-acetyl), 1703 (C = O, N-acetyl),
1684 (C = O), 1543 and 1453 (C = C, phenyl ring); [1]
H NMR (200 MHz, DMSO-d6, δ, TMS = 0, J = Hz): 8.51
(s, 1H, H-4), 8.45 (d, 1H, J = 7.0, H-7′), 8.35 (s, 1H, H-2′),
7.95 (dd, 1H, J = 5.2 and 7.2, H-6′) 7.95 (dd, 1H, J = 5.2
and 7.2, H-5′), 7.48 to 7.38 (m, 4H, H-4′, 5′, 6′, 7′), 2.67
(s, 3H, N-acetyl ), 2.67 (s, 3H, O-acetyl ); [13] C NMR
(125 MHz, DMSO-d6, δ, TMS= 0, J =Hz): 170.00, 168.93,
158.82, 148.78, 144.48, 139.62, 137.20, 135.50, 128.3,
128.27, 126.55, 125.70, 125.40, 125.00, 124.29, 12.05,
121.00, 120.90, 116.49, 114.98, 24.30, 20.81; MS: 386
(M + Na)+; Anal. calcd. For C20H13NO6: C, 66.12; H,
3.61; N, 3.86; found C, 66.24; H, 3.42; N, 3.88
Biological evaluation
In vitro cytotoxicity against five human cancer cell lines
was determined using 96-well tissue culture plate [26].
The cells were allowed to grow in carbon dioxide incu-
bator (37°C) for 24 h. Test materials in complete growth
medium (100 μl) were added after 24 h of incubation to
the wells containing cell suspension. The plates were
further incubated for 48 h in a carbon dioxide incuba-
tor. The cell growth was stopped by gentle layering
trichloroacetic acid (50%, 50 μl) on top of the medium
in all the wells. The plates were incubated at 4°C for 1 h
to fix the cells attached to the bottom of the wells. The
liquid of all the wells was gently pipetted out and
discarded. The plates were washed five times with
distilled water to remove trichloroacetic acid, growth
medium low-molecular weight metabolites, serum
proteins, etc. and air-dried. The plates were stained with
sulforhodamine B dye (0.4% in 1% acetic acid, 100 μl)
for 30 min. The plates were washed five times with 1%
acetic acid and then air-dried [27]. The adsorbed dye
was dissolved in Tris–HCl buffer (100 μL, 0.01 M,
pH 10.4), and the plates were gently stirred for 10 min
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recorded on ELISA reader at 540 nm. The cell growth
was determined by subtracting the mean OD value of
respective blank from the mean OD value of the experi-
mental set. Percent growth in presence of test material
was calculated considering the growth in the absence of
any test material as 100%, and in turn, percent growth
inhibition in presence of test material was calculated.
Conclusions
A series of novel combretastatin analogues have been
synthesized by condensation of indole-3-acetic acid with
different substituted aldehydes, and structures were es-
tablished by various spectral techniques like IR, MS,
and NMR ([1] H, [13] C, HMBC, and HSQC). Confi-
guration was established by lactone formation when
hydroxyl group was present on second position of alde-
hyde. Further, it was confirmed by nOe (H-4′ intensity
increased on double irradiation of H-3). Compounds
were evaluated for anticancer activity. The effect on
microtubule structure was determined using confocal
microscopy dose-dependent disruption, and loss of
microtubules indicates apoptosis by 2d. Binding of
compound at colchicine binding site was established by
molecular docking study. It was helpful to rationalize
the inhibitory activity of these inhibitors. The carbonyl
oxygen (carbonyl group at indole) forms a hydrogen
bond with sulfhydryl group of Cys241β. This is similar
to the interaction of colchicines with the tubulin. An-
other hydrogen bond was formed between the hydroxyl
group of the carboxylic acid part of 2d and nitrogen of
Leu255β. These two hydrogen bonds play a crucial role
in stabilizing the conformation of 2d at the colchicine
binding site. The activity of the synthesized compounds
indicates that these can be promising anticancer drugs.
To confirm their potency, further in vivo experiment
will be required to address the anticancer property in
cancer chemotherapy.
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